<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, unclassifiable, with features intermediate between diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) and Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) (intermediate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), is a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group with some features resembling <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> and others resembling <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we report a case of intermediate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> in a Korean child </plain></SENT>
<SENT sid="2" pm="."><plain>A 2-yr-old male was admitted for evaluation and management of left hip pain </plain></SENT>
<SENT sid="3" pm="."><plain>Immunohistochemistry of a biopsy of the femur neck revealed <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells positive for CD20, CD10, BCL2, BCL6, and Ki67 </plain></SENT>
<SENT sid="4" pm="."><plain>A bone marrow (BM) aspirate smear revealed that 49.3% of <z:hpo ids='HP_0000001'>all</z:hpo> nucleated cells were abnormal lymphoid cells, composed of large- and medium-sized cells </plain></SENT>
<SENT sid="5" pm="."><plain>Immunophenotyping of the neoplastic cells revealed positivity for CD19, CD10, CD20, and sIg lambda and negativity for CD34, Tdt, and myeloperoxidase (MPO) </plain></SENT>
<SENT sid="6" pm="."><plain>Cytogenetic and FISH analyses showed a complex karyotype, including t(8;14)(q24.1;q32) and IGH-MYC fusion </plain></SENT>
<SENT sid="7" pm="."><plain>Intensive chemotherapy was initiated, including <z:chebi fb="0" ids="8382">prednisone</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, L-asparaginase, <z:chebi fb="0" ids="41977">daunorubicin</z:chebi>, and central <z:mp ids='MP_0008912'>nervous</z:mp> system prophylaxis with intrathecal <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX) and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>One month after the initial diagnosis, BM examination revealed the persistent of abnormal lymphoid cells; cerebrospinal fluid cytology, including cytospin, showed atypical lymphoid cells </plain></SENT>
<SENT sid="9" pm="."><plain>The patient was treated again with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, <z:chebi fb="0" ids="8382">prednisone</z:chebi>, adriamycin, MTX, and intrathecal MTX and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>The patient died of <z:hpo ids='HP_0100806'>sepsis</z:hpo> 5 months after the second round of chemotherapy </plain></SENT>
</text></document>